F. Hoffmann-La Roche AG

Switzerland

Back to Profile

1-100 of 7,954 for F. Hoffmann-La Roche AG Sort by
Query
Aggregations
IP Type
        Patent 7,349
        Trademark 605
Jurisdiction
        World 6,216
        Canada 1,366
        Europe 199
        United States 173
Date
New (last 4 weeks) 27
2024 July (MTD) 11
2024 June 33
2024 May 33
2024 April 31
See more
IPC Class
A61P 35/00 - Antineoplastic agents 755
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants 574
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum 471
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids 392
C07D 487/04 - Ortho-condensed systems 382
See more
NICE Class
05 - Pharmaceutical, veterinary and sanitary products 492
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services 107
41 - Education, entertainment, sporting and cultural services 84
09 - Scientific and electric apparatus and instruments 80
42 - Scientific, technological and industrial services, research and design 70
See more
Status
Pending 509
Registered / In Force 7,445
  1     2     3     ...     80        Next Page

1.

DETECTION OF MODIFIED NUCLEOBASES IN DNA SAMPLES

      
Application Number EP2024050590
Publication Number 2024/149841
Status In Force
Filing Date 2024-01-11
Publication Date 2024-07-18
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE SEQUENCING SOLUTIONS, INC. (USA)
Inventor
  • Chandrasekar, Jagadeeswaran
  • Horsman, Joseph W.
  • Kokoris, Mark Stamatios
  • Mcruer, Robert N.
  • Prindle, Marc
  • Tabone, John C.

Abstract

Described are methods of detecting modified nucleotide bases in a DNA sample using specific DNA glycosylases to excise a modified nucleobase of interest. Prior to glycosylase treatment, DNA target fragments are copied by a DNA polymerase to produce a complementary copy strand that preserves the genetic information of the DNA target strand. Following glycosylase treatment, the DNA target fragments are repaired by either ligating across the gaps to produce a deletion at each position of the modified nucleobase of interest or filling in the gaps with a single non-native nucleotide to produce a base substitution at each position of the modified nucleobase of interest. Comparison of the DNA sequences of the two strands of the target fragments enables identification of the positions of the modified nucleotide base in the DNA target fragment.

IPC Classes  ?

  • C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

2.

SULFONYLVINYL COMPOUNDS FOR THE TREATMENT OF CANCER

      
Application Number EP2024050517
Publication Number 2024/149819
Status In Force
Filing Date 2024-01-11
Publication Date 2024-07-18
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Chen, Jianguo
  • Liu, Haixia
  • Shen, Hong
  • Zhang, Weixing
  • Zhao, Dan
  • Zhu, Wei

Abstract

The present invention relates to compounds of formula (I), wherein R1to R7, A1and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.

IPC Classes  ?

  • C07D 487/04 - Ortho-condensed systems
  • C07D 487/12 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains three hetero rings
  • C07D 513/12 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains three hetero rings
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
  • A61P 35/00 - Antineoplastic agents
  • A61K 31/5025 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems

3.

TREATMENT OF CANCER USING A HLA-A2/WT1 X CD3 BISPECIFIC ANTIBODY AND VENETOCLAX/AZACITIDINE

      
Application Number EP2024050523
Publication Number 2024/149821
Status In Force
Filing Date 2024-01-11
Publication Date 2024-07-18
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Colombetti, Sara
  • Eckmann, Jan
  • Haenel, Gerulf
  • Klein, Christian
  • Schoenle, Anne
  • Subklewe, Sabine Marion

Abstract

The present invention relates to the treatment of cancer, in particular to the treatment of cancer using a HLA-A2/WT1 x CD3 bispecific antibody and venetoclax/azacitidine.

IPC Classes  ?

  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
  • A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61P 35/00 - Antineoplastic agents

4.

AMD ARRAY

      
Application Number 1798468
Status Registered
Filing Date 2024-04-26
Registration Date 2024-04-26
Owner F. Hoffmann-La Roche AG (Switzerland)
NICE Classes  ? 42 - Scientific, technological and industrial services, research and design

Goods & Services

Scientific services; research in the field of ophthalmology.

5.

ALPHSYNTAG

      
Application Number 1797256
Status Registered
Filing Date 2024-04-22
Registration Date 2024-04-22
Owner F. Hoffmann-La Roche AG (Switzerland)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations.

6.

AKDIFDY

      
Application Number 1797257
Status Registered
Filing Date 2024-04-22
Registration Date 2024-04-22
Owner F. Hoffmann-La Roche AG (Switzerland)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations.

7.

BAUMANNII (CRAB)

      
Application Number EP2023087524
Publication Number 2024/141442
Status In Force
Filing Date 2023-12-22
Publication Date 2024-07-04
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE MOLECULAR SYSTEMS, INC. (USA)
Inventor
  • Cady, Kyle C.
  • Lin, Patrick
  • Moghaddasi, Arrash
  • Nguyen, Hai
  • Sathish, Aishwarya
  • Somanathan, Indira
  • Sorenson, Natacha
  • Zhuang, Xun

Abstract

The present invention relates to compositions and methods to detect the Acinetobacter calcoaceticus- Acinetobacter baumannii complex species and to identify the most prevalent carbapenemases found in carbapenem resistant Acinetobacter calcoaceticus-baumannii (CRAB) such as blaOXA-23-like, blaOXA-24-like, blaOXA-58-like and blaNDM-like by a multiplex real-time PCR assay.

IPC Classes  ?

  • C12Q 1/6851 - Quantitative amplification
  • C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

8.

BENZIMIDAZOLE DERIVATIVES USEFUL AS SIK MODULATORS

      
Application Number EP2023087526
Publication Number 2024/141443
Status In Force
Filing Date 2023-12-22
Publication Date 2024-07-04
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Awale, Mahendra
  • Berchtold, Stefan
  • Charpentier, Julie
  • Colombano, Héloïse Marie Albine
  • Décoret, Guillaume
  • Groebke Zbinden, Katrin
  • Grossmann, Nicole
  • Haap, Wolfgang
  • Harris, Philip Anthony
  • Hert, Jérôme
  • Kallenbach, Jonah Milton
  • Kramer, Christian
  • Kreis, Lukas
  • Krumm, Danny
  • Lucas Cabré, Xavier
  • Manevski, Nenad
  • Pflieger, Philippe
  • Pourmousa Abkenar, Amir Mohsen
  • Rauber, Etienne
  • Tan, Dazhi
  • Wach, Jean-Yves
  • Wermuth, Roger

Abstract

The invention relates to a compound of formula (I), (I) wherein L, R1, R2and R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

IPC Classes  ?

  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
  • A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
  • A61P 43/00 - Drugs for specific purposes, not provided for in groups
  • C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
  • C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
  • A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
  • A61K 31/50 - Pyridazines; Hydrogenated pyridazines

9.

NEW BENZIMIDAZOLE DERIVATIVES

      
Application Number EP2023087527
Publication Number 2024/141444
Status In Force
Filing Date 2023-12-22
Publication Date 2024-07-04
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Awale, Mahendra
  • Berchtold, Stefan
  • Charpentier, Julie
  • Colombano, Héloïse Marie Albine
  • Décoret, Guillaume
  • Groebke Zbinden, Katrin
  • Grossmann, Nicole
  • Haap, Wolfgang
  • Harris, Philip Anthony
  • Hert, Jérôme
  • Kallenbach, Jonah Milton
  • Kramer, Christian
  • Kreis, Lukas
  • Krumm, Danny
  • Lucas Cabré, Xavier
  • Manevski,, Nenad
  • Pflieger, Philippe
  • Pourmousa Abkenar, Amir Mohsen
  • Rauber, Etienne
  • Tan, Dazhi
  • Wach, Jean-Yves
  • Wermuth, Roger

Abstract

The invention relates to a compound of formula (I) wherein L, A1, R1, R2and R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

IPC Classes  ?

  • C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
  • C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
  • C07D 471/04 - Ortho-condensed systems
  • C07D 487/04 - Ortho-condensed systems
  • C07D 498/04 - Ortho-condensed systems
  • A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
  • A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
  • A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
  • A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

10.

ALFSYNPRA

      
Application Number 1797258
Status Registered
Filing Date 2024-04-22
Registration Date 2024-04-22
Owner F. Hoffmann-La Roche AG (Switzerland)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations.

11.

DIGITAL PCR ASSAY DESIGNS FOR MULTIPLE HEPATITIS B VIRUS GENE TARGETS AND NON-EXTENDABLE BLOCKER OLIGONUCLEOTIDES THEREFOR

      
Application Number EP2023087631
Publication Number 2024/141476
Status In Force
Filing Date 2023-12-22
Publication Date 2024-07-04
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE MOLECULAR SYSTEMS, INC. (USA)
Inventor
  • Hamilton, Aaron Thaddeus
  • Dawson, Paul Joshua
  • Scott, Elizabeth Marie
  • Mano, Calvin
  • Sun, Jingtao
  • Yang, Wei

Abstract

The present invention provides compositions and methods relating to novel digital PCR (dPCR) assay designs (droplet digital or other systems) for the detection and quantitation of multiple hepatitis B virus (HBV) gene targets. The compositions and method can further include non-extendible blocker oligonucleotides for reduction of non-specific inter-amplicon extension.

IPC Classes  ?

  • C12Q 1/6816 - Hybridisation assays characterised by the detection means
  • C12Q 1/6848 - Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction

12.

BATTERY RELAXATION WITH NON-CONFORMING BLUETOOTHR COMMUNICATION BEHAVIOR

      
Application Number US2022082005
Publication Number 2024/136893
Status In Force
Filing Date 2022-12-20
Publication Date 2024-06-27
Owner
  • ROCHE DIABETES CARE, INC. (USA)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIABETES CARE GMBH (Germany)
Inventor Bootz, Felix

Abstract

A computer implemented method for conserving power during BLUETOOTH® communication performed by a BLUETOOTH® enabled peripheral computing device, the method comprising advertising availability of the BLUETOOTH® enabled peripheral computing device for pairing, receiving a scan request from a BLUETOOTH® enabled central computing device, transmitting a scan response to the BLUETOOTH® enabled central computing device in response to the scan request, establishing a connection with the BLUETOOTH® enabled central computing device, monitoring a power consumption indicator of the peripheral computing device, introducing a delay period to a response period to a connection event received from the central computing device if the monitored power consumption indicator meets at least one predefined criteria, and wherein the delayed response period causes the response to occur after a predetermined peripheral latency period but prior to a supervision timeout.

IPC Classes  ?

  • H04W 52/02 - Power saving arrangements
  • H04B 7/00 - Radio transmission systems, i.e. using radiation field
  • H04W 92/00 - Interfaces specially adapted for wireless communication networks
  • H04W 76/00 - Connection management

13.

ANALYTICAL METHOD OF DETERMINING AT LEAST ONE PROPERTY OF A SAMPLE OF A BODILY FLUID

      
Application Number EP2023086548
Publication Number 2024/133203
Status In Force
Filing Date 2023-12-19
Publication Date 2024-06-27
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIABETES CARE GMBH (Germany)
  • ROCHE DIABETES CARE, INC. (USA)
Inventor
  • Berg, Max
  • Hailer, Fredrik
  • Limburg, Bernd

Abstract

An analytical system and an analytical method of determining at least one property of at least one sample of a bodily fluid are disclosed. The method comprises using at least one first mobile device (112) and at least one second mobile device (114), each of said mobile devices (112, 114) comprising at least one camera (116) and at least one processor (118). At least one first image is captured by the first mobile device (112) before applying the sample of the bodily fluid to a reagent test region (122). The first image is stored together with one time stamp and at least one first item of identity information in a database (128). The second mobile device (114) captures at least one second image and determines by using the stored information of the first mobile device (112) in the database (128) the at least one property of the sample.

IPC Classes  ?

  • G01N 21/84 - Systems specially adapted for particular applications

14.

(POLY)LABEL SIGNAL ENHANCER

      
Application Number EP2023086953
Publication Number 2024/133457
Status In Force
Filing Date 2023-12-20
Publication Date 2024-06-27
Owner
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Freisler, Joerg
  • Heindl, Dieter
  • Hillringhaus, Lars
  • Karaca, Samir
  • Kobold, Uwe
  • Kuchelmeister, Hannes
  • Weiser, Stefan

Abstract

A first aspect of the invention is related to the use of a (poly)label for generating a quantifiable signal for an analyte of interest in mass spectrometry, wherein the (poly)label has the structure (I). In a second aspect, the invention is directed to a process for modifying an analyte of interest for obtaining an increased intensity signal in mass spectrometry. A third aspect of the invention is directed to a method for determining an analyte of interest by mass spectrometry. A fourth aspect of the invention relates to a (poly)label having structure of formula (Ia). In a fifth aspect, the invention is related to a reaction product comprising a polypeptide and a (poly)label having the general structure (III).

IPC Classes  ?

  • G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

15.

AUTOMATED ANALYSIS DEVICE

      
Application Number JP2023043522
Publication Number 2024/135350
Status In Force
Filing Date 2023-12-05
Publication Date 2024-06-27
Owner
  • HITACHI HIGH-TECH CORPORATION (Japan)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Sakai Tatsuya
  • Miyake Yuka
  • Hamasaki Koshin
  • Voelker Markus

Abstract

This automated analysis device comprises a first analyzing unit for performing analysis related to a first analysis item group, a second analyzing unit for performing analysis of a second analysis item group using a measuring principle different from the first analyzing unit, a reagent storage unit for storing at least one first reagent vessel accommodating a reagent used for the analysis by the first analyzing unit and at least one second reagent vessel for accommodating a reagent used for the analysis by the second analyzing unit, an agitating unit for agitating a solution in the second reagent vessel, and a control unit for controlling operation of the agitating unit, wherein the control unit controls the operation of the agitating unit to agitate a solution in the first reagent vessel. This makes it possible to agitate a plurality of reagents used for a plurality of measurements that employ different principles, while suppressing an increase in the size of the device.

IPC Classes  ?

  • G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
  • G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor

16.

METHOD OF DETERMINING A NUMERICAL ANALYTE RESULT VALUE

      
Application Number EP2023086510
Publication Number 2024/133177
Status In Force
Filing Date 2023-12-19
Publication Date 2024-06-27
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIABETES CARE GMBH (Germany)
  • ROCHE DIABETES CARE, INC. (USA)
Inventor
  • Berg, Max
  • Limburg, Bernd
  • Hailer, Fredrik

Abstract

A computer-implemented method of determining a numerical analyte result value corresponding to a concentration of an analyte in a sample of a bodily fluid of a subject applied to a reagent test region, comprising step (a) determining a numerical analyte result value based on an image of the reagent test region by using an algorithm which takes into account one or more parameters, each parameter being adapted to take more than one value, step (b) displaying the numerical analyte result value and/or a corresponding analyte value range and/or a corresponding message on a display device and step (c) automatically checking for available updated values for one or more of the parameters on a remote server before executing step (a), and for each available updated value updating the corresponding parameter value to be taken into account in step (a).

IPC Classes  ?

  • G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis

17.

METHOD FOR ENHANCED DETERMINATION OF ANALYTE CONCENTRATION IN BODILY FLUID

      
Application Number EP2023086778
Publication Number 2024/133357
Status In Force
Filing Date 2023-12-20
Publication Date 2024-06-27
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIABETES CARE GMBH (Germany)
  • ROCHE DIABETES CARE, INC. (USA)
Inventor
  • Limburg, Bernd
  • Berg, Max
  • Hailer, Fredrik

Abstract

thresh- old(m)estimateestimateappl-range(n)appl-range(n)appl-range(n) selected in step ii).

IPC Classes  ?

  • G01N 21/84 - Systems specially adapted for particular applications

18.

PROCCESSES FOR THE PREPARATION OF AN NLRP3 INHIBITOR

      
Application Number EP2023087167
Publication Number 2024/133610
Status In Force
Filing Date 2023-12-21
Publication Date 2024-06-27
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Apuri, Satyender
  • Bandaru, Sreenivasulu
  • Bharatha, Mallesh
  • Chiliveri, Raghavendra Badu
  • Cinqualbre, Joséphine Eliette Françoise
  • Fraser, Paul
  • Ireddy, Prathap
  • Kaldre, Dainis
  • Mondière, Régis Jean Georges
  • Palguna, Jetta
  • Stutz, Alfred
  • Tosatti, Paolo

Abstract

N1,2,3,5,6,7N1,2,3,5,6,7-33 inhibition.

IPC Classes  ?

19.

SOLID PHASE PEPTIDE SYNTHESIS (SPPS) SOLVENT SYSTEM

      
Application Number EP2023087269
Publication Number 2024/133685
Status In Force
Filing Date 2023-12-21
Publication Date 2024-06-27
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Winter, Nils
  • Hillringhaus, Lars

Abstract

The present invention relates to a solid phase peptide synthesis (SPPS) solvent system and use thereof. The present invention further relates to a solid phase peptide synthesis (SPPS), a kit, a peptide synthesizer and the use thereof.

IPC Classes  ?

  • C07K 1/04 - General processes for the preparation of peptides on carriers
  • C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
  • C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids

20.

BATTERY RELAXATION WITH NON-CONFORMING BLUETOOTH COMMUNICATION BEHAVIOR

      
Application Number US2023084491
Publication Number 2024/137430
Status In Force
Filing Date 2023-12-18
Publication Date 2024-06-27
Owner
  • ROCHE DIABETES CARE, INC. (USA)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIABETES CARE GMBH (Germany)
Inventor Bootz, Felix

Abstract

A computer implemented method for conserving power during BLUETOOTH® communication performed by a BLUETOOTH® enabled peripheral computing device, the method comprising advertising availability of the BLUETOOTH® enabled peripheral computing device for pairing, receiving a scan request from a BLUETOOTH® enabled central computing device, transmitting a scan response to the BLUETOOTH® enabled central computing device in response to the scan request, establishing a connection with tire BLUETOOTH® enabled central computing device, monitoring a power consumption indicator of the peripheral computing device, introducing a delay period to a response period to a connection event received from the central computing device if the monitored power consumption indicator meets at least one predefined criteria, and wherein the delayed response period causes the response to occur after a predetermined peripheral latency period but prior to a supervision timeout.

IPC Classes  ?

  • H04W 52/02 - Power saving arrangements
  • H04B 7/00 - Radio transmission systems, i.e. using radiation field
  • H04W 92/00 - Interfaces specially adapted for wireless communication networks
  • H04W 76/00 - Connection management

21.

PROCESS FOR THE PREPARATION OF A QUINAZOLINONE DERIVATIVE

      
Application Number EP2023085728
Publication Number 2024/126634
Status In Force
Filing Date 2023-12-14
Publication Date 2024-06-20
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Dott, Pascal
  • Fantasia, Serena Maria
  • Guillemot-Plass, Maud
  • Kaldre, Dainis
  • Lari, Giacomo Marco
  • Modolo-Chellat, Isabelle Huguette
  • Sedelmeier, Joerg
  • Trokowski, Sebastian

Abstract

The present invention relates to a new process for the preparation of (3R)-N-[2-cyano-4- fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide, as well as to a novel intermediate useful for the synthesis of said compound at large scale.

IPC Classes  ?

  • C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

22.

TNA ANTISENSE OLIGONUCLEOTIDES TARGETING ACTL6B

      
Application Number EP2023085762
Publication Number 2024/126654
Status In Force
Filing Date 2023-12-14
Publication Date 2024-06-20
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Bastien, Jessica Marine Aurore
  • Bleicher, Konrad
  • Li, Meiling
  • Schaeublin, Adrian
  • Vikesaa, Jonas

Abstract

The present invention relates to antisense oligonucleotide splice modulators of actin-like 6B (ACTL6B). These antisense oligonucleotide splice modulators are complementary, such as fully complementary, to the ACTL6B precursor-mRNA, and are capable of increasing or restoring expression of ACTL6B in TDP-43 depleted cells, such as for use in conditions and medical indications where TDP-43 is functionally depleted.

IPC Classes  ?

  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • A61K 31/7088 - Compounds having three or more nucleosides or nucleotides

23.

COMBINATION THERAPY FOR CANCER TREATMENT

      
Application Number EP2023085770
Publication Number 2024/126660
Status In Force
Filing Date 2023-12-14
Publication Date 2024-06-20
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Eckmann, Jan
  • Pettazzoni, Piergiorgio Francesco Tommaso
  • Schnetzler, Gabriel
  • Wichmann, Juergen
  • Dott, Pascal
  • Fantasia, Serena Maria
  • Guillemot-Plass, Maud
  • Kaldre, Dainis
  • Lari, Giacomo Marco
  • Modolo-Chellat, Isabelle Huguette
  • Sedelmeier, Joerg
  • Trokowski, Sebastian

Abstract

Provided herein are combination therapies comprising a BRAF inhibitor (e.g., a compound of formula (I), or a pharmaceutically acceptable salt thereof) and an EGRF inhibitor (EGRFi), as well as pharmaceutical compositions, methods and uses thereof.

IPC Classes  ?

  • C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
  • A61P 35/00 - Antineoplastic agents
  • A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

24.

METHODS FOR TREATING CANCER

      
Application Number EP2023085960
Publication Number 2024/126750
Status In Force
Filing Date 2023-12-14
Publication Date 2024-06-20
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Ammann, Johannes Ulrich
  • Bustillos Rodriguez, Alberto Edgardo
  • Castro Sanchez, Amparo Yovanna
  • Mueller-Ohldach, Mathis Daniel

Abstract

The present invention relates to methods for treating cancer in a subject using a cancer immunotherapy such as a PD-L1 binding protein, such as an anti-PD-L1 antibody (e.g. atezolizumab) in combination with implementing a digital patient monitoring method that comprises receiving reports of one or more predetermined symptoms, whether the reported symptoms are in at least a first category or a second category, and in response to receiving a report of a predetermined symptom in said subject in the first category, performing a first action comprising providing self-management information specific to the predetermined symptom to the subject, wherein the predetermined symptoms are cancer and cancer immunotherapy-specific.

IPC Classes  ?

  • G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61P 35/00 - Antineoplastic agents
  • C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
  • G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
  • G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

25.

DETECTING AND QUANTIFYING HYPERREFLECTIVE FOCI (HRF) IN RETINAL PATIENTS

      
Application Number US2023083890
Publication Number 2024/129894
Status In Force
Filing Date 2023-12-13
Publication Date 2024-06-20
Owner
  • HOFFMANN-LA ROCHE INC. (USA)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
Inventor
  • Lu, Huanxiang
  • Maunz, Andreas
  • Cohen, Yaniv
  • Jones, Ian Lloyd

Abstract

A method for identifying hyperreflective foci (HRF) in an eye of a patient includes accessing one or more optical coherence tomography (OCT) scans of a retina of the eye of the patient, and inputting the one or more OCT scans into one or more machine-learning models trained to segment the one or more OCT scans to identify a set of hyperreflective entities detectable from the one or more OCT scans. The method further includes determining, based on the segmented one or more OCT scans, one or more diametral measurements corresponding to each of the identified set of hyperreflective entities, and identifying hyperreflective foci (HRF) in the retina of the eye of the patient based on whether at least one of the one or more diametral measurements satisfy a diametral threshold.

IPC Classes  ?

26.

CIMKRASVA

      
Application Number 019042173
Status Pending
Filing Date 2024-06-17
Owner F. Hoffmann-La Roche AG (Switzerland)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations.

27.

DEVKRASDA

      
Application Number 019042256
Status Pending
Filing Date 2024-06-17
Owner F. Hoffmann-La Roche AG (Switzerland)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations.

28.

SULFONYL DERIVATIVES AS CCR6 INHIBITORS

      
Application Number EP2023084028
Publication Number 2024/121013
Status In Force
Filing Date 2023-12-04
Publication Date 2024-06-13
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Bautista, Lady Johanna
  • Cals, Joseph Maria Gerardus Barbara
  • De Brouwer, Johanna Hendrika Angelique
  • De Kimpe, Vera
  • Deretey, Eugen
  • Lazo Mori, Alger Ayrton
  • Manders, Daan Marten Jorrit
  • Nabuurs, Sander Bernardus

Abstract

The present invention provides new derivatives having the general formula (I), (I) wherein R1, R2, R3, R4, R5, R6, R7, X1, X2, X3, X4, and X5 are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

IPC Classes  ?

  • C07D 209/42 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D 209/46 - Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
  • C07D 211/96 - Sulfur atom
  • C07D 213/64 - One oxygen atom attached in position 2 or 6
  • C07D 213/81 - Amides; Imides
  • C07D 213/82 - Amides; Imides in position 3
  • C07D 217/24 - Oxygen atoms
  • C07D 237/14 - Oxygen atoms
  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 471/04 - Ortho-condensed systems
  • C07D 487/04 - Ortho-condensed systems
  • C07C 323/22 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
  • A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
  • A61P 37/02 - Immunomodulators

29.

INHIBITORS OF NLRP3

      
Application Number EP2023084416
Publication Number 2024/121184
Status In Force
Filing Date 2023-12-06
Publication Date 2024-06-13
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Bouche, Lea Aurelie
  • Guba, Wolfgang
  • Jaeschke, Georg
  • Mesch, Stefanie Katharina
  • Patiny-Adam, Angélique
  • Schnider, Christian
  • Shannon, Jonathan Martin
  • Steiner, Sandra
  • Tosstorff, Andreas Michael

Abstract

The invention relates to novel compounds having the general formula (I), (I) wherein R1, R2, X and W are as described herein, composition including the compounds and methods of using the compounds.

IPC Classes  ?

  • C07D 471/04 - Ortho-condensed systems
  • C07D 498/04 - Ortho-condensed systems
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61P 37/00 - Drugs for immunological or allergic disorders
  • A61K 31/5025 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems

30.

A METHOD FOR AUTOMATED MICROSCOPIC SCANNING

      
Application Number EP2023084735
Publication Number 2024/121321
Status In Force
Filing Date 2023-12-07
Publication Date 2024-06-13
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor Salzmann, Wenzel

Abstract

A method for automated microscopic scanning is disclosed. The method comprises the following steps: a. (110) image data acquisition, wherein the image data acquisition comprises generating microscopic images of a sample by scanning at least one pre-defined scanning area of at least one microscopic slide (128)carrying the sample by using at least one image scanner (122); b. (112) determining at least one feature characterizing at least one biological entity of the sample by applying at least one classification algorithm to the microscopic images by using at least one processing device, wherein the feature is compared to at least one pre-defined criterion, wherein the determining and the comparing is performed in parallel to the image data acquisition, wherein the image data acquisition of said microscopic slide (128) is discontinued by at least one controlling device of the image scanner (122) as soon as the determined feature reaches the pre- defined criterion; and c. repeating the method for a next microscopic slide (128).

IPC Classes  ?

  • G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts

31.

NOVEL COMPOUNDS AS MODULATORS OF NLRP3 INHIBITION

      
Application Number EP2023084200
Publication Number 2024/121086
Status In Force
Filing Date 2023-12-05
Publication Date 2024-06-13
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Bouche, Lea Aurelie
  • Guba, Wolfgang
  • Jaeschke, Georg
  • Johnston, Heather Jennifer
  • Mesch, Stefanie Katharina
  • Shannon, Jonathan Martin
  • Steiner, Sandra

Abstract

The invention relates to novel compounds having the general formula (I), wherein R1, R2, R3, R4, R5, and R6, are as described herein, composition including the compounds and methods of using the compounds.

IPC Classes  ?

  • C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
  • C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
  • C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
  • A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
  • A61P 11/06 - Antiasthmatics
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

32.

SYSTEM AND METHOD FOR TOTAL NUCLEIC ACID LIBRARY PREPARATION VIA TEMPLATE-SWITCHING

      
Application Number EP2023084672
Publication Number 2024/121293
Status In Force
Filing Date 2023-12-07
Publication Date 2024-06-13
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • KAPA BIOSYSTEMS, INC. (USA)
Inventor
  • Adams, Nicolette
  • Van Der Merwe, Ruben Gerhard
  • Ranik, Martin
  • Visser, Johan Christiaan
  • Mcallister Wadsworth, Ross Iain
  • Van Der Walt, Eric

Abstract

The present disclosure provides a method for carrying out a template-switching reaction on a nucleic acid sample including at least one double-stranded DNA and at least one RNA. The method includes performing a first template-switching reaction on the nucleic acid sample in the absence of at least one dNTP selected from dATP, dCTP, dGTP, and dTTP, thereby forming a first nucleic acid product comprising the double-stranded DNA having at least one extended 3' end complementary to a first template-switch oligonucleotide. The method further includes performing a second template-switching reaction on the nucleic acid sample, thereby forming a second nucleic acid product comprising a first primer extension product complementary to at least a portion of the RNA, the first primer extension product having an extended 3' end complementary to the second template-switch oligonucleotide.

IPC Classes  ?

  • C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

33.

METHOD AND SYSTEM FOR PREDICTING AND/OR DETECTING THE PRESENCE OF A LESION

      
Application Number EP2023084749
Publication Number 2024/121329
Status In Force
Filing Date 2023-12-07
Publication Date 2024-06-13
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Albrecht, Thomas Felix
  • Arus Pous, Josep
  • Cohen, Yaniv
  • Funk, Juergen Michael
  • Schumacher, Vanessa Lea
  • Clément, Grégoire

Abstract

The present invention relates to a computer-implemented method of predicting and/or detecting the presence of a lesion in a human or animal tissue, the method comprising: identifying a tissue type based on image data of the human or animal tissue using a first model, and predicting and/or detecting the presence of a lesion in the tissue based on the image data and the tissue type using a second model.

IPC Classes  ?

  • G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks

34.

SYSTEM, METHOD AND GRAPHICAL USER INTERFACE FOR MANAGING QUALITY CONTROL FOR A DIAGOSTIC SYSTEM

      
Application Number EP2023084971
Publication Number 2024/121417
Status In Force
Filing Date 2023-12-08
Publication Date 2024-06-13
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE MOLECULAR SYSTEMS, INC. (USA)
Inventor
  • Nguyen, Michael
  • Fitch, Connor

Abstract

A system, a method, and a user interface are described for customizing external quality control testing for a diagnostic system. Quality control assays must be run for each assay panel capable of being run on a diagnostic instrument. Each quality control assay for each assay panel is given a desired frequency and a desired rotation. A QC rule customization module allows a user to create, manage, delete, or view QC rules. Reminders can be sent for upcoming quality control assays that are due. Alerts are sent if the quality control assays are missed.

IPC Classes  ?

  • G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
  • G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis

35.

CRYSTALLINE SALT FORM OF ATR INHIBITOR

      
Application Number US2023082761
Publication Number 2024/123932
Status In Force
Filing Date 2023-12-06
Publication Date 2024-06-13
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Egli, Andre
  • Webber, Luca

Abstract

Disclosed is the phosphate salt of the compound of structure (I). Also disclosed is a crystalline form of the phosphate salt, the methods of making the phosphate salt and uses thereof.

IPC Classes  ?

  • C07D 491/04 - Ortho-condensed systems
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
  • A61P 35/00 - Antineoplastic agents
  • A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems

36.

CLUSTER-BASED HISTOPATHOLOGY PHENOTYPE REPRESENTATION LEARNING BY SELF-SUPERVISED MULTI-CLASS TOKEN HIERARCHICAL VISION TRANSFORMER

      
Application Number US2023083003
Publication Number 2024/124071
Status In Force
Filing Date 2023-12-07
Publication Date 2024-06-13
Owner
  • VENTANA MEDICAL SYSTEMS, INC. (USA)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
Inventor
  • Miri, Mohammad Saleh
  • Kalra, Shivam
  • Ye, Jiarong

Abstract

The system and method for processing a digital pathology image using a machine learning model that includes a self-supervised hierarchical Vision Transformer (ViT) configured to perform unsupervised clustering with multiple classification tokens. The method includes receiving a digital pathology image that depicts a tissue slice stained with histological dyes. The digital pathology image may be processed to generate a result comprising multiple predicted classifications of individual patches of the digital pathology image. The result is generated by a machine-learning model using a self-supervised hierarchical Vision Transformer (ViT) that may further comprise a multi-head self-attention module configured to predict a crosspatch relevance metric using an attention mechanism for each individual patch in the digital pathology image thereby assigning the individual patches to a cluster based on the crosspatch relevance metrics.

IPC Classes  ?

37.

CD47 BLOCKING AGENT AND ANTI-CD20 / ANTI-CD3 BISPECIFIC ANTIBODY COMBINATION THERAPY

      
Application Number US2023083080
Publication Number 2024/124107
Status In Force
Filing Date 2023-12-08
Publication Date 2024-06-13
Owner
  • PFIZER INC. (USA)
  • HOFFMANN-LA ROCHE INC. (USA)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
Inventor
  • Bruns, Ingmar
  • Lincha, Victor, Ruberio
  • Lundberg, Linda, Maria
  • Relf, James, Christopher
  • Scheuber, Anita
  • Wang, Diane, Dan
  • Wang, Yibo

Abstract

Dosing regimens and methods for administering combination therapies combining a CD47 blocking agent and an anti-CD20 / anti-CD3 bispecific antibody are provided. The dosing regimens and methods may further include additional therapeutic agents.

IPC Classes  ?

  • A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

38.

MANAGING INTEGRATION OF A MEDICAL DEVICE INTO A COMPUTING PLATFORM

      
Application Number US2023080905
Publication Number 2024/118431
Status In Force
Filing Date 2023-11-22
Publication Date 2024-06-06
Owner
  • GENENTECH, INC. (USA)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Wacinski, Tomasz Albert
  • Dridi, Abdesslem

Abstract

The present disclosure relates to techniques for integrating a medical device into a digital health platform. Particularly, aspects are directed to identifying subject data of a subject associated with a medical device; determining one or more parameters associated with administering a treatment to the subject using the medical device based on the subject data; sending a notification to a client device associated with the subject; receiving, from the client device associated with the subject, an authentication procedure, wherein the authentication procedure includes a client authentication blockchain hash associated with the client device and a medical device authentication blockchain hash associated with the medical device; verifying an association of the client authentication blockchain hash and the medical device authentication blockchain hash with the subject; and approving an administration of the treatment to the subject in response to verifying the association.

IPC Classes  ?

  • G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
  • G16H 40/60 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
  • G06F 16/00 - Information retrieval; Database structures therefor; File system structures therefor
  • G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
  • G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
  • G06F 21/31 - User authentication
  • G06F 21/44 - Program or device authentication

39.

SAMPLE PROCESSING AGNOSTIC IMAGE REPRESENTATION LEARNING FOR DIGITAL PATHOLOGY

      
Application Number US2023082165
Publication Number 2024/119130
Status In Force
Filing Date 2023-12-01
Publication Date 2024-06-06
Owner
  • GENENTECH, INC. (USA)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Gao, Zijun
  • Nguyen, Trung Kien
  • Gildenblat, Jacob
  • Abbasi-Sureshjani, Samaneh
  • Dhalluin, Paul Mb

Abstract

Described herein are systems, methods, and programming for analyzing and classifying digital pathology images agnostic to sample processing techniques used to prepare the digital pathology images. In some embodiments, image data including a first image set and a second image set may be obtained. The first and second image sets may be processed using a first and second slide preparation machine, respectively. A first augmented view set and a second augmented view set may be generated based on augmentations applied to the first and second image sets. For each image, a first vision transformer to may be trained to: generate a first representation of an augmented view of the first augmented view set, and enhance a similarity between the first representation and a second representation of an augmented view of the second augmented view set. The second representation may be generated via a second vision transformer.

IPC Classes  ?

40.

METHOD FOR OPERATING AN IN-VITRO-DIAGNOSTICS LABORATORY SYSTEM AND IN-VITRO-DIAGNOSTICS LABORATORY SYSTEM

      
Application Number EP2023082975
Publication Number 2024/115303
Status In Force
Filing Date 2023-11-24
Publication Date 2024-06-06
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Benton, Daniel
  • Ehrenreich, Sebastian
  • Hellwig, Marcel
  • Toro, Daniel Gomez

Abstract

The present disclosure refers to a method for operating an in-vitro-diagnostics laboratory system, IVD laboratory system. The IVD laboratory system has a housing (12) with an opening (12a); an actuator device (10), arranged in the housing (12), for processing sample containers; a cover (11) configured to cover the opening (12a); a cooling device (14) configured to cool the sample containers; and a cooling device control unit (15) configured to control operation of the cooling device (14). The method comprises: determining whether the cover (11) is open; determining whether the cooling device control unit (15) is active; in a normal system mode, disabling operation of the actuator device (10) based on at least one of the cover (11) being open and the cooling device control unit (15) being inactive; and in a bypass system mode, enabling operation of the actuator device (10) based on the cover (11) being open and the cooling device control unit (15) being active.

IPC Classes  ?

  • G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
  • G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
  • G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms

41.

DIGITAL IMAGE ANALYSIS

      
Application Number EP2023083242
Publication Number 2024/115422
Status In Force
Filing Date 2023-11-28
Publication Date 2024-06-06
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Albrecht, Thomas
  • Arus Pous, Josep

Abstract

The present invention relates to systems, methods and products for analyzing digital images, in particular digital pathology images.

IPC Classes  ?

  • G06V 10/20 - Image preprocessing
  • G06V 10/70 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning
  • G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts

42.

IMPROVED CANCER IMMUNOTHERAPY

      
Application Number EP2023083098
Publication Number 2024/115349
Status In Force
Filing Date 2023-11-27
Publication Date 2024-06-06
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Gasser, Stephan
  • Groebke Zbinden, Katrin
  • Murgia, Claudio
  • Schmidt, Tobias
  • Sorrentino, Antonio
  • Umaña, Pablo

Abstract

The present invention relates to combination therapies employing T cell activation and UAP1 inhibitors, and the use of these combination therapies for the treatment of cancer.

IPC Classes  ?

  • A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
  • A61K 31/7024 - Esters of saccharides
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61P 35/00 - Antineoplastic agents

43.

METHOD OF OPERATING A GRIPPING DEVICE

      
Application Number EP2023083203
Publication Number 2024/115406
Status In Force
Filing Date 2023-11-27
Publication Date 2024-06-06
Owner
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
Inventor
  • Vasile, Teodor-Laurentiu
  • Ali-Mahmoud, Yanis
  • Alesch, Carsten

Abstract

The invention relates to a method of operating a gripping device (100) being adapted to insert sample containers (1) into sample container racks (2) and/or remove sample containers (1) from sample container racks (2), wherein the gripping device (100) comprises gripping fingers (3) being adapted to grip the sample containers (1), wherein the method comprises the steps: moving the gripping fingers (3) in z-direction to insert a sample container (1) into a sample container rack (2) or remove a sample container (1) from a sample container rack (2), determining, if the gripping fingers (3) get in contact with the sample container rack (2), and performing an error procedure, if the gripping fingers (3) get in contact with the sample container rack (2).

IPC Classes  ?

  • B25J 15/08 - Gripping heads having finger members
  • B25J 19/00 - Accessories fitted to manipulators, e.g. for monitoring, for viewing; Safety devices combined with or specially adapted for use in connection with manipulators
  • G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor

44.

DETECTION OF AN ANALYTE OF INTEREST BY A CHIP BASED NANOESI DETECTION SYSTEM

      
Application Number EP2023083791
Publication Number 2024/115685
Status In Force
Filing Date 2023-11-30
Publication Date 2024-06-06
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Rempt, Martin
  • Seitz, Manuel Josef
  • Zuth, Christoph

Abstract

The present invention relates to a method, a diagnostic system, a kit and the use thereof for efficiently detection of an analyte of interest by a chip based nanoESI detection system.

IPC Classes  ?

  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals

45.

YASERD

      
Application Number 019034272
Status Pending
Filing Date 2024-05-30
Owner F. Hoffmann-La Roche AG (Switzerland)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations.

46.

DERIVATISATION AGENT FOR LASER DESORPTION IONIZATION MASS SPECTROMETRY

      
Application Number EP2023082387
Publication Number 2024/110385
Status In Force
Filing Date 2023-11-20
Publication Date 2024-05-30
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Bernicke, Dirk
  • Hahn, Robert
  • Heindl, Dieter
  • Kuchelmeister, Hannes
  • Loibl, Simon
  • Mazzier, Daniela
  • Prencipe, Giuseppe
  • Rempt, Martin
  • Seitz, Manuel Josef
  • Zuth, Christoph

Abstract

In a first aspect, the invention relates to a derivatisation agent, preferably derivatisation agent for analytes intended to be analysed via LDI-MS, comprising a structural element of formula (I) C- L1 -Z - (L2)p - X, wherein C is a chromophore having an absorption maximum in the range of from 280 to 400 nm; Z is a charged unit comprising at least one permanently charged moiety; X is a reactive group; L1, L2 are each a linker unit; and p is either zero or 1. A second aspect of the invention is related to a kit comprising the derivatisation agent according to the first aspect. In a third aspect, the invention is directed to a use of the derivatisation agent according to the first aspect for the mass spectrometric determination of an analyte molecule, wherein the mass spectrometric determination is LDI-MS. A fourth aspect of the invention relates to a conjugate of a derivatisation agent according to the first aspect and an analyte, wherein the conjugate has the structure of formula (II) C- L1 - Z - (L2)p - Xa - Ya - A, wherein C, L1, L2, p, Z and N are as defined in the context of the first aspect; Xa is a remainder of a reactive group X as defined in the context of the first aspect; A is the analyte and Ya is the remainder of a reactive group Y bound to the analyte A, which has reacted with the reactive group X of the derivatisation agent thus forming a covalent bound between Xa and Ya. A fifth aspect of the invention is related to a method for the mass spectrometric determination of an analyte molecule comprising the steps: (a) providing an analyte of interest; (b) providing a derivatisation agent comprising a structure of formula (I) as defined in the context of the first aspect; (c) reacting the analyte provided according to (a) with the derivatisation agent provided according to (b), whereby a conjugate of the analyte and the derivatisation agent is formed, and (d) subjecting the conjugate formed in (c) to a mass spectrometric analysis, wherein the mass spectrometric analysis is preferably LDI-MS.

IPC Classes  ?

  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N 33/74 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones

47.

METHOD FOR DETERMINING AT LEAST ONE ANALYTE OF INTEREST

      
Application Number EP2023082470
Publication Number 2024/110422
Status In Force
Filing Date 2023-11-21
Publication Date 2024-05-30
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Bergmann, Frank
  • Hagedorn, Kay
  • Heindl, Dieter
  • Rempt, Martin

Abstract

The present invention relates to a method for determining at least one analyte of interest and the uses thereof. The present invention further relates to a diagnostic system, a kit and the use thereof for determining at least one analyte of interest.

IPC Classes  ?

48.

GESERDLI

      
Application Number 019034285
Status Pending
Filing Date 2024-05-30
Owner F. Hoffmann-La Roche AG (Switzerland)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations.

49.

JESERDAC

      
Application Number 019034286
Status Pending
Filing Date 2024-05-30
Owner F. Hoffmann-La Roche AG (Switzerland)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations.

50.

METHOD FOR INCREASING RECOMBINANT PROTEIN EXPRESSION

      
Application Number EP2023082474
Publication Number 2024/110426
Status In Force
Filing Date 2023-11-21
Publication Date 2024-05-30
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Bruenker, Peter
  • Geiger, Martina
  • Auslaender, Simon
  • Goepfert, Ulrich

Abstract

Herein is reported a nucleic acid comprising in operably linked form a nucleic acid encoding a selection marker, a nucleic acid encoding a self-cleaving peptide sequence, and a nucleic acid encoding a proteinaceous protease inhibitor. Further reported are methods for the recombinant production of a heterologous polypeptide using said nucleic acid as well as a cell comprising said nucleic acid according to the invention. Likewise reported is the use of the nucleic acid according to the invention for increasing the amount of the recombinantly produced heterologous polypeptide by reducing protease cleavage.

IPC Classes  ?

  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • C07K 14/81 - Protease inhibitors
  • C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
  • C12N 15/62 - DNA sequences coding for fusion proteins
  • C12N 15/65 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers

51.

ARYL THIOETHERS AS HIF-2ALPHA INHIBITORS

      
Application Number EP2023081549
Publication Number 2024/104932
Status In Force
Filing Date 2023-11-13
Publication Date 2024-05-23
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Ding, Dong
  • Wang, Xiaoqing
  • Wu, Yao
  • Xu, Hongtao
  • Zhang, Zhisen
  • Zou, Ge

Abstract

The present invention provides novel compounds having the general formula: (I) wherein R1to R6, X, Y, and Z are as described herein, or a pharmaceutically acceptable salt thereof, compositions including the compounds and methods of using the compounds.

IPC Classes  ?

  • C07D 221/04 - Ortho- or peri-condensed ring systems
  • A61P 37/00 - Drugs for immunological or allergic disorders
  • C07D 317/64 - Oxygen atoms
  • C07C 1/00 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon

52.

QUINAZOLINONE COMPOUND AS BRAF INHIBITOR FOR THE TREATMENT OF ADVANCED SOLID CANCER OR METASTASES

      
Application Number EP2023082007
Publication Number 2024/105144
Status In Force
Filing Date 2023-11-16
Publication Date 2024-05-23
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Brigo, Alessandro
  • Kornacker, Martin
  • Kratochwil, Nicole A.
  • Peter, Stefanie
  • Pettazzoni, Piergiorgio Francesco Tommaso
  • Rynn, Caroline
  • Schnetzler, Gabriel

Abstract

The present invention is directed to (3R)-N-[2-cyano-4-fluoro-3-(3-methyl-4-oxo- quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide or a pharmaceutically acceptable salt thereof, for novel uses in the treatment of locally advanced solid tumours, in particular melanoma with brain metastases. The present invention also relates to pharmaceutical composition comprising (3R)-N-[2-cyano-4-fluoro-3-(3-methyl-4-oxo- quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

  • A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
  • A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61P 35/04 - Antineoplastic agents specific for metastasis
  • A61P 35/00 - Antineoplastic agents

53.

A NOVEL BIOMARKER TO PREDICT EFFICACY OF CANCER IMMUNOTHERAPY

      
Application Number EP2023081548
Publication Number 2024/104931
Status In Force
Filing Date 2023-11-13
Publication Date 2024-05-23
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Charo, Jehad
  • Dejardin, David

Abstract

The present invention provides a novel biomarker comprising a composite score of T cell density in paired biopsies taken before and after treatment of a patient, with cancer, to inform potential outcomes in immunotherapy, including but not limited to clinical trials. The invention also provides methods to determine whether a cancer patient is likely to benefit from immunotherapy by using said biomarker.

IPC Classes  ?

  • G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
  • G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

54.

ANTIGEN BINDING MOLECULES

      
Application Number EP2023081550
Publication Number 2024/104933
Status In Force
Filing Date 2023-11-13
Publication Date 2024-05-23
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Abu Tarbush, Jamal
  • Bransi, Ali
  • Challier, John
  • Frost, Sofia
  • Georges, Guy
  • Hesse, Friederike
  • Imhof-Jung, Sabine
  • Klein, Christian
  • Lariviere, Laurent

Abstract

The present invention relates to a pair of binding molecules comprising complementary parts of an effector domain, such binding molecules being capable of forming a functional effector domain when bound to their target antigens on the surface of a cell. Specifically, the invention relates to a pair of binding molecules wherein the complementary parts of the effector domain are complemented with inert complementing domains while the functional effector domain is not formed, providing advantageous properties, such as produceability, stability and/or biological functionality, to the binding molecules.

IPC Classes  ?

  • C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes

55.

MEDICAL DEVICE FOR DETECTING AT LEAST ONE ANALYTE IN A BODY FLUID

      
Application Number EP2023081553
Publication Number 2024/104935
Status In Force
Filing Date 2023-11-13
Publication Date 2024-05-23
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIABETES CARE GMBH (Germany)
  • ROCHE DIABETES CARE, INC. (USA)
Inventor Bootz, Felix

Abstract

The present invention relates to medical device for detecting at least one analyte in a body fluid, comprising a base body for attaching the medical device to a patient's body; an insertable analyte sensor comprising an insertable portion; and an electronics unit operably connected to the insertable analyte sensor, wherein the insertable analyte sensor comprises a first electrode and a second electrode, both, forming part of the insertable portion, wherein the first electrode extending from a second end towards its first free end and the second electrode extending from a second end towards its first free end are configured to be, during use of the medical device, at least partially in electric contact with the body tissue of a user. In order to mitigate a risk of an uncontrolled electric current flowing into a user's body, the electrical resistance of the first and second electric conductor is higher than the electrical resistance of the first electrode and second electrode.

IPC Classes  ?

  • A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using enzyme electrodes, e.g. with immobilised oxidase

56.

RECOMBINANT BINDING PROTEINS WITH ACTIVATABLE EFFECTOR DOMAIN

      
Application Number EP2023081671
Publication Number 2024/104988
Status In Force
Filing Date 2023-11-14
Publication Date 2024-05-23
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Brinkmann, Ulrich
  • Buldun, Can Martin
  • Dickopf, Steffen
  • Vasic, Vedran

Abstract

The present invention relates to a pair of recombinant binding proteins and its uses, e.g. for activation of an effector domain upon binding to a target cell. Specifically, the invention relates to the pair of recombinant binding proteins and pharmaceutical compositions comprising said pair of recombinant binding proteins.

IPC Classes  ?

  • C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
  • C07K 16/46 - Hybrid immunoglobulins

57.

MULTI-MODAL MACHINE LEARNING APPROACHES FOR PREDICTING CANCER TYPE AND GLEASON GRADE LEVERAGING PUBLIC TCGA DATA

      
Application Number EP2023081973
Publication Number 2024/105134
Status In Force
Filing Date 2023-11-15
Publication Date 2024-05-23
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE MOLECULAR SYSTEMS INC. (USA)
Inventor
  • Ashtari, Mohammad
  • Etz Hadar, Ofir
  • Gildenblat, Jacob
  • King, Michael
  • Klaiman, Eldad
  • Vladimirova, Antoaneta Petkova
  • Witkowski, Jakub
  • Wohlfart, Christian

Abstract

The invention relates to a method of diagnosing or determining the prognosis of cancer in a patient, the method comprising processing, using RNA‐sequencing and a first machine learning model, the genomic data of the patient to determine at least one of a first cancer type or degree of cancer and processing, using histopathology and a second machine learning model, the biopsy image data of the patient to determine at least one of a second cancer type or degree of cancer and comparing the determined first type or degree of cancer with the determined second type or degree of cancer and correlating the two.

IPC Classes  ?

58.

TIGTUGO

      
Application Number 1789910
Status Registered
Filing Date 2024-03-07
Registration Date 2024-03-07
Owner F. Hoffmann-La Roche AG (Switzerland)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations.

59.

COMPOSITIONS AND METHODS OF TREATING CHILDHOOD ONSET IDIOPATHIC NEPHROTIC SYNDROME

      
Application Number US2023078951
Publication Number 2024/102734
Status In Force
Filing Date 2023-11-07
Publication Date 2024-05-16
Owner
  • GENENTECH, INC. (USA)
  • HOFFMANN-LA ROCHE INC. (USA)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
Inventor
  • Lehane, Patricia, Bernadette
  • Omachi, Theodore, Ari
  • Cheng, Ji

Abstract

The present disclosure provides methods for treating childhood-onset idiopathic nephrotic syndrome (INS), or reducing risk and/or frequency of relapse from childhood-onset INS, in an individual that is greater than or equal to 2 years of age and less than or equal to 25 years of age. In some embodiments, the methods comprise administering to the individual an effective amount of obinutuzumab.

IPC Classes  ?

  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

60.

TRIAZINONE DERIVATIVES AS NLRP3 INHIBITORS

      
Application Number EP2023080895
Publication Number 2024/099992
Status In Force
Filing Date 2023-11-07
Publication Date 2024-05-16
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Bouche, Lea Aurelie
  • Guba, Wolfgang
  • Jaeschke, Georg
  • Mesch, Stefanie Katharina
  • Shannon, Jonathan Martin
  • Steiner, Sandra
  • Tosstorff, Andreas Michael

Abstract

The invention relates to novel compounds having the general formula (I) wherein R1, R2, R3, R4and R5 are as described herein, composition including the compounds and methods of using the compounds.

IPC Classes  ?

  • C07D 471/04 - Ortho-condensed systems
  • A61P 11/06 - Antiasthmatics
  • A61P 25/16 - Anti-Parkinson drugs
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

61.

TRIAZINONE DERIVATIVES AS NLRP3 INHIBITORS

      
Application Number EP2023080899
Publication Number 2024/099993
Status In Force
Filing Date 2023-11-07
Publication Date 2024-05-16
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Alanine, Thomas Alexander
  • Bouche, Lea Aurelie
  • Guba, Wolfgang
  • Jaeschke, Georg
  • Mesch, Stefanie Katharina
  • Shannon, Jonathan Martin
  • Tosstorff, Andreas Michael

Abstract

The invention relates to novel compounds having the general formula (I) wherein R1, R2, R3, R4a, R4b, and R5 are as described herein, composition including the compounds and methods of using the compounds.

IPC Classes  ?

  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • A61P 11/06 - Antiasthmatics
  • A61P 25/16 - Anti-Parkinson drugs
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

62.

TRIAZINONE DERIVATIVES AS NLRP3 INHIBITORS

      
Application Number EP2023080902
Publication Number 2024/099996
Status In Force
Filing Date 2023-11-07
Publication Date 2024-05-16
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Bouche, Lea Aurelie
  • Guba, Wolfgang
  • Jaeschke, Georg
  • Mesch, Stefanie Katharina
  • Shannon, Jonathan Martin

Abstract

The invention relates to a novel compound having the formula 6-[[(3R)-1-Ethyl-3-piperidyl]amino]-3-(4-hydroxyindan-5-yl)-4-methyl-1,2,4-triazin-5-one or 6-[[(3R)-1-ethyl-3-piperidyl]amino]-3-(2-hydroxy-3-bicyclo[4.2.0]octa-1,3,5-trienyl)-4-methyl-1,2,4-triazin-5-one, and pharmaceutically acceptable salts thereof, compositions including the compound and methods of using the compound.

IPC Classes  ?

  • A61P 11/06 - Antiasthmatics
  • A61P 25/16 - Anti-Parkinson drugs
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

63.

ANTIBODIES BINDING TO HLA-A*02/FOXP3

      
Application Number EP2023081236
Publication Number 2024/100170
Status In Force
Filing Date 2023-11-09
Publication Date 2024-05-16
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Bransi, Ali
  • Bujotzek, Alexander
  • Hanisch, Lydia Jasmin
  • Klein, Christian
  • Klostermann, Stefan
  • Kreymborg, Anna Katharina
  • Mueller, Corina Anna
  • Surówka, Marlena

Abstract

The invention provides antibodies that bind to HLA-A*02/FOXP3, including mono and multispecific antibodies, e.g. for activating T cells. Additionally, the present invention provides polynucleotides and vectors encoding such antibodies, and host cells comprising such polynucleotides or vectors. The invention further relates to methods for producing the antibodies, pharmaceutical compositions comprising the antibodies and to methods of using them in the treatment of disease.

IPC Classes  ?

  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

64.

TIAGENITY

      
Application Number 1789911
Status Registered
Filing Date 2024-03-07
Registration Date 2024-03-07
Owner F. Hoffmann-La Roche AG (Switzerland)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations.

65.

A GRIPPING DEVICE CONFIGURED FOR GRIPPING AT LEAST ONE SLIDE

      
Application Number EP2023081027
Publication Number 2024/100058
Status In Force
Filing Date 2023-11-07
Publication Date 2024-05-16
Owner
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE MOLECULAR SYSTEMS, INC. (USA)
Inventor
  • Leinberger, Falko
  • Osswald, Denny
  • Soccio, Timeo

Abstract

A gripping device (150) configured for gripping at least one slide (168) is disclosed. The gripping device (150) comprises: • at least one first gripping element (110), wherein the first gripping element (110) comprises at least one first contact surface (112) for gripping the slide (168); • at least one second gripping element (134), wherein the second gripping element (134) comprises at least one second contact surface (136) for gripping the slide (168), wherein the second gripping element (134) further comprises at least two protrusions (160) which respectively extend essentially perpendicular to the second contact surface (136), wherein the at least two protrusions (160) are located on opposing ends (162) of the second contact surface (136), wherein the at least two protrusions (160) are configured for centering the slide (168) during gripping the slide (168) via the gripping device (150); wherein the first gripping element (110) and the second gripping element (134) are linearly movable relative to one another, wherein the first contact surface (112) of the first gripping element (110) and the second contact surface (136) of the second gripping element (134) face each other.

IPC Classes  ?

  • G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
  • B01L 9/00 - Supporting devices; Holding devices

66.

ENZYMATIC ASYMMETRIC SYNTHESES OF N-ALKYL AMINO ACIDS

      
Application Number US2023037019
Publication Number 2024/102404
Status In Force
Filing Date 2023-11-08
Publication Date 2024-05-16
Owner
  • GENENTECH, INC. (USA)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Molinaro, Carmela
  • Kelly, Sean M.
  • Iding, Hans
  • Stocker, Patrik Franz
  • Linghu, Xin
  • Bruetsch, Tobias Michael
  • Herold, Sebastian

Abstract

The subject matter described herein is directed to methods of preparing compounds of general Formula I: or a salt or solvate thereof.

IPC Classes  ?

  • C12P 13/04 - Alpha- or beta-amino acids
  • C12P 17/12 - Nitrogen as only ring hetero atom containing a six-membered hetero ring
  • C12P 41/00 - Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
  • C07C 271/18 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms

67.

METHOD FOR PRODUCING GLYCOPROTEIN COMPOSITIONS

      
Application Number EP2023079453
Publication Number 2024/094457
Status In Force
Filing Date 2023-10-23
Publication Date 2024-05-10
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Boyd, Marina Luise
  • Klinger, Christian

Abstract

The present invention relates to a method for recombinantly producing a glycoprotein composition comprising at least one glycoprotein comprising the step of cultivating a recombinant host cell which expresses the glycoprotein in a cultivation medium in a bioreactor having a pH measuring device positioned in the bioreactor and configured to be in physical contact with the cultivation medium, characterized in that (a) the cultivating is performed under sterile conditions, (b) the pH value measured with the pH measuring device differs by 0.05 units or less from the pH value of the cultivation medium, and (c) the relative content of at least one glycosylated variant in the glycoprotein composition has reduced batch-to-batch variability, compared to a method where the pH value measured by the pH measuring device differs by more than 0.05 units, preferably by more than 0.03 units, from the pH value in the cultivation medium, and thereby producing the glycoprotein composition. The present invention further relates to the use of a method for carbon dioxide based pH calibration for improving batch-to-batch variability.

IPC Classes  ?

  • C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
  • G01N 27/416 - Systems

68.

MEDICAL DISPENSING DEVICE

      
Application Number EP2023080641
Publication Number 2024/094836
Status In Force
Filing Date 2023-11-03
Publication Date 2024-05-10
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIABETES CARE GMBH (Germany)
  • ROCHE DIABETES CARE, INC. (USA)
Inventor Von Campenhausen, Harald

Abstract

The present invention relates to a medical dispensing device comprising a first cylindrical reservoir, a second cylindrical reservoir, a first plunger movably arranged within the first cylindrical reservoir, a second plunger movably arranged within the second cylindrical reservoir, and a drive that is configured for moving the first plunger within the first cylindrical reservoir and that is further configured for moving the second plunger within the second cylindrical reservoir. For an improved dosing accuracy, the drive is configured to selectively move either the first plunger or the second plunger, and in that the drive is further configured to stop moving the first plunger within the first cylindrical reservoir when the first plunger reaches the ending point within the first cylindrical reservoir, and to start moving the second plunger within the second cylindrical reservoir.

IPC Classes  ?

  • A61M 5/14 - Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
  • A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
  • A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
  • A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically

69.

MEDICAL INFUSION DEVICE SYSTEM HAVING A DOSING RANGE EXTENSION

      
Application Number EP2023080642
Publication Number 2024/094837
Status In Force
Filing Date 2023-11-03
Publication Date 2024-05-10
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIABETES CARE GMBH (Germany)
  • ROCHE DIABETES CARE, INC. (USA)
Inventor Von Campenhausen, Harald

Abstract

The present invention relates to a medical infusion device system comprising a first dosing chamber for delivering at least a first minimum dosing amount of a liquid medicament, a second dosing chamber for delivering at least a second minimum dosing amount of the liquid medicament, a fluid line operatively coupled to the first dosing chamber and the second dosing chamber for conveying a total amount of liquid medicament for delivering by the first and second dosing chamber to an outlet of the fluid line, and a controller to control the total amount of liquid medicament. In order to provide relatively small and large dosing amounts both fast and accurate the second minimum dosing amount of the liquid medicament provided by the second dosing chamber larger than the first minimum dosing amount of the liquid medicament provided by the first dosing chamber.

IPC Classes  ?

  • A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
  • A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
  • A61M 5/14 - Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
  • A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
  • A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic

70.

ISOTOPE LABELED AND NON-LABELED GENTAMICIN C CONGENERS

      
Application Number EP2023080207
Publication Number 2024/094607
Status In Force
Filing Date 2023-10-30
Publication Date 2024-05-10
Owner
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Huber, Florian Mauritius Erasmus
  • Schmidt, Richard R.
  • Siebenhaar, Joanna
  • Voss, Edgar

Abstract

The present invention generally relates to the field of isotope labeled and non-labeled gentamicin congeners and synthetic methods for the preparation of such congeners. In particular, the present invention relates to isotope labeled gentamicin C or a salt or solvate or derivative thereof, the gentamicin C comprising at least one 13C, D and/or 15N atom and methods for the preparation of gentamicin C or salt or solvate or derivate thereof, in particular of gentamicin C comprising at least one 13C, D and/or 15N atom or salt or solvate or derivate thereof.

IPC Classes  ?

  • C07H 15/236 - Cyclohexane rings, substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2 a saccharide radical being substituted by an alkylamino radical in position 3 and by two substituents different from hydrogen in position 4, e.g. gentamicin complex, sisomicin, verdamicin
  • C07H 1/00 - Processes for the preparation of sugar derivatives
  • C07B 59/00 - Introduction of isotopes of elements into organic compounds
  • A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins

71.

COMBINATION THERAPY WITH ANTI-CD19/ANTI-CD28 BISPECIFIC ANTIBODY

      
Application Number EP2023080438
Publication Number 2024/094741
Status In Force
Filing Date 2023-11-01
Publication Date 2024-05-10
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Herter, Sylvia
  • Hofer, Thomas
  • Klein, Christian
  • Sam, Johannes
  • Umaña, Pablo

Abstract

The present invention relates to combination therapies employing an anti-CD20/anti-CD3 bispecific antibody in combination with an anti-CD19/anti-CD28 bispecific antibody and a CD19-targeted 4-1BB (CD137) agonist and the use of these combination therapies for the treatment of B-cell cancer such as diffuse large B cell lymphoma (DLBCL).

IPC Classes  ?

  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • C07K 16/46 - Hybrid immunoglobulins

72.

PREDICTING RESPONSE TO IL-6 ANTAGONISTS

      
Application Number EP2023079391
Publication Number 2024/088921
Status In Force
Filing Date 2023-10-23
Publication Date 2024-05-02
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Mesquida, Marina
  • Nogoceke, Everson

Abstract

The invention is concerned with a method of predicting response to an IL-6 angatonist such as anti-IL-6 antibody by determing the concentration of IL-6 in human aqueous humor. The invention is also concerned with an IL-6 angatonist for use in treatment of uveitis or uveitic macular edema.

IPC Classes  ?

  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • A61P 27/02 - Ophthalmic agents

73.

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL)

      
Application Number EP2023079392
Publication Number 2024/088922
Status In Force
Filing Date 2023-10-23
Publication Date 2024-05-02
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Benz, Joerg
  • Giroud, Maude
  • Grether, Uwe
  • Kuhn, Bernd
  • O'Hara, Fionn Susannah
  • Ritter, Martin
  • Rombach, Didier
  • Schmid, Philipp Claudio
  • Wittwer, Matthias Beat

Abstract

The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L, W, Y, Z, and R1to R3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

IPC Classes  ?

  • C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
  • C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
  • C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
  • C07D 471/04 - Ortho-condensed systems
  • C07D 471/10 - Spiro-condensed systems
  • C07D 487/10 - Spiro-condensed systems
  • A61P 25/04 - Centrally acting analgesics, e.g. opioids
  • A61P 25/24 - Antidepressants
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
  • A61P 35/00 - Antineoplastic agents
  • A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
  • A61K 31/4196 - 1,2,4-Triazoles
  • A61K 31/4245 - Oxadiazoles
  • A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
  • A61K 31/433 - Thiadiazoles
  • A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
  • A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems

74.

PROCESS FOR MANUFACTURING ALOGABAT

      
Application Number EP2023079404
Publication Number 2024/088928
Status In Force
Filing Date 2023-10-23
Publication Date 2024-05-02
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Guillemot-Plass, Maud
  • Jenny, Christian
  • Koerner, Matthias
  • Modolo-Chellat, Isabelle Georgette Huguette
  • Scalone, Michelangelo

Abstract

The invention relates to novel processes for manufacturing 6-[[5-methyl-3-(6-methyl-3- pyridyl)isoxazol-4-yl]methoxy]-N-tetrahydropyran-4-yl-pyridazine-3-carboxamide (1), or a pharmaceutically acceptable salt thereof. The processes according to the invention are particularly suitable for large-scale manufacturing of the compound of formula 1 under GMP conditions.

IPC Classes  ?

  • C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
  • A61P 25/20 - Hypnotics; Sedatives
  • A61K 31/501 - Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings

75.

A SAMPLE CARRIER TRANSPORT DEVICE

      
Application Number EP2023079430
Publication Number 2024/088938
Status In Force
Filing Date 2023-10-23
Publication Date 2024-05-02
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
  • HITACHI HIGH-TECH CORPORATION (Japan)
Inventor
  • Belz, Renato
  • Graf, Michael
  • Yasui, Akihiro
  • Ueno, Saki
  • Maeshima, Muneo

Abstract

A sample carrier transport device (116) for transporting sample carriers (110) to a work- station (112) for sample processing is disclosed. The sample carrier transport device (116) comprises a surface (128) having a plurality of sample carrier holder portions (130). Each of the sample carrier holder portions (130) is configured for removably holding at least one sample carrier (110) during transport of the sample carrier (110) to the workstation (112). The surface (128) is configured for performing a movement for transporting the sample carrier (110) to the workstation (112). The sample carrier transport device (116) comprises at least one lifting mechanism configured for moving the surface (128) to at least one transport position and to at least one transfer position. The transport position and the transfer position refer to different heights of the surface (128). The lifting mechanism is configured for holding the surface (128) during transport of the sample carriers (110) to the workstation (112) in the transport position. The sample carrier transport device (116) is configured for handing over the sample carrier (110) to the workstation (112) and for receiving the sample carrier (110) from the workstation (112) in the transfer position.

IPC Classes  ?

  • G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations

76.

COMBINATION THERAPY FOR THE TREATMENT OF CANCER

      
Application Number EP2023079524
Publication Number 2024/088987
Status In Force
Filing Date 2023-10-24
Publication Date 2024-05-02
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Amann, Maria
  • Boetsch, Christophe
  • Eckmann, Jan
  • Ferlini, Cristiano
  • Karanikas, Vaios
  • Kolben, Theresa
  • Marrer-Berger, Estelle
  • Gonzalez Nicolini, Maria Valeria
  • Schnetzler, Gabriel
  • Sutmuller, Roger Paulus Maria
  • Umaña, Pablo

Abstract

The present invention is directed to the combination of a TCB, as defined herein, and a Treg cell depletion therapy, for example an anti-CD25 antibody for use in the treatment of cancer.

IPC Classes  ?

  • A61P 35/00 - Antineoplastic agents
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

77.

DETERMINING HPLC METHOD PARAMETERS USING MACHINE LEARNING

      
Application Number EP2023079867
Publication Number 2024/089143
Status In Force
Filing Date 2023-10-26
Publication Date 2024-05-02
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Burwood, Ryan Paul
  • Zimmerli, Pascal Manuel

Abstract

Computer-implemented methods for predicting HPLC retention time for one or more compounds using machine learning models are disclosed. In particular, the use of machine learning models for identifying a set of HPLC method parameters suitable for separating two or more compounds in a composition is disclosed. Related systems and products are also described.

IPC Classes  ?

78.

PREDICTING TILE-LEVEL CLASS LABELS FOR HISTOPATHOLOGY IMAGES

      
Application Number US2023077343
Publication Number 2024/086750
Status In Force
Filing Date 2023-10-19
Publication Date 2024-04-25
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Iftikhar, Saadia
  • Korski, Konstanty
  • Yuce, Anil
  • Abbasi-Sureshjani, Samaneh

Abstract

A method implemented by one or more computer devices includes providing weakly-supervised neural networks for analysis of histopathology images. The method includes accessing a histopathology image including a slide-level class label. The method includes extracting a plurality of regions of pixels of the histopathology image at a plurality of magnifications. For each of the extracted plurality of regions of pixels, the method further includes inputting the region of pixels into a machine-learning model trained to generate a prediction of a class label for the region of pixels based on the region of pixels and the slide-level class label and outputting the prediction of the class label for the region of pixels. The method includes generating a prediction of one or more tile-level class labels for the histopathology image based on the predictions of class labels for each of the extracted plurality of regions of pixels.

IPC Classes  ?

  • G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
  • G06T 7/00 - Image analysis
  • G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts

79.

FILTRATION SYSTEM, METHOD FOR PREDICTING A MAINTENANCE CONDITION OF THE FILTRATION SYSTEM AND METHOD FOR PREDICTING A RECOVERY CONDITION OF THE FILTRATION SYSTEM

      
Application Number EP2023078619
Publication Number 2024/083714
Status In Force
Filing Date 2023-10-16
Publication Date 2024-04-25
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Munoz Rodriguez De Guzman, Carlos
  • Zahn, Hans

Abstract

A method for predicting a maintenance condition of a filtration system of a diagnostic apparatus or a laboratory analyser at a given time is done by performing the following steps. First a plurality of successive raw permeability values of the permeability of a fluid through the filtration device over a specified measurement period is measured. Then smoothed permeability values are determined by means of a data processing method to reduce the fluctuations of the raw permeability values over time. Afterwards a regression analysis function is applied through the successive permeability values, wherein the regression analysis function comprises fitting parameters being adapted so that the fitting function is fitted to the measured permeability values. Finally, the time, when the regression analysis function will cross a predetermined threshold value is determined, wherein the crossing of the threshold value is judged as a maintenance condition.

IPC Classes  ?

  • B01D 65/02 - Membrane cleaning or sterilisation
  • B01D 65/08 - Prevention of membrane fouling or of concentration polarisation

80.

DETECTION OF ABNORMALITY IN SPECIMEN IMAGE

      
Application Number EP2023078869
Publication Number 2024/083853
Status In Force
Filing Date 2023-10-17
Publication Date 2024-04-25
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor Bruenggel, Nils

Abstract

Detection of abnormality in specimen image A computer-implemented method of detecting the presence of morphologically abnormal cells in a specimen image comprises: receiving electronic image data representative of a specimen image, the specimen image depicting a plurality of cells; applying an analytical model to each of a plurality of subsets of the image data, each subset corresponding to a respective portion of the specimen image which depicts a single cell, the analytical model configured to output, for each subset of the image data: a value parameterizing a property of the cell; and either a confidence score or an uncertainty score associated with the value, thereby generating output data comprising the plurality of confidence scores or plurality of uncertainty scores; and determining, based on the output data, whether one or more morphologically abnormal cells are likely to be present in the specimen image.

IPC Classes  ?

  • G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
  • G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
  • G06V 10/80 - Fusion, i.e. combining data from various sources at the sensor level, preprocessing level, feature extraction level or classification level

81.

INSERTION SYSTEM AND METHOD FOR INSERTING A MEDICAL DEVICE

      
Application Number EP2023079091
Publication Number 2024/083960
Status In Force
Filing Date 2023-10-19
Publication Date 2024-04-25
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIABETES CARE GMBH (Germany)
  • ROCHE DIABETES CARE, INC. (USA)
Inventor Roscher, Olaf

Abstract

An insertion device for inserting at least part of a medical device into a subject comprising a chamber for receiving the medical device, an insertion tool for inserting an insertable portion of the medical device, an insertion mechanism, a retraction mechanism for retracting the insertion tool from the subject after insertion, a retaining mechanism for retaining the insertion tool in an end position after retraction, an inner housing comprising the retaining mechanism and the retracted insertion tool in the end position, an inserter housing comprising the insertion mechanism as well as a chamber for receiving the inner housing, wherein the inserter housing is formed of recyclable or biodegradable or compostable material, the insertion device comprises an ejection mechanism to remove the inner housing from the chamber when the insertion tool is retrained within the inner housing by the retaining mechanism, and the ejection mechanism is activatable by the user.

IPC Classes  ?

  • A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value

82.

DETECTION OF MODIFIED NUCLEOBASES IN NUCLEIC ACID SAMPLES

      
Application Number EP2023079149
Publication Number 2024/083982
Status In Force
Filing Date 2023-10-19
Publication Date 2024-04-25
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE SEQUENCING SOLUTIONS, INC. (USA)
Inventor
  • Busam, Robert
  • Prindle, Marc
  • Tabone, John
  • Lehmann, Alexander
  • Chandrasekar, Jagadeeswaran
  • Kokoris, Mark Stamatios
  • Mcruer, Robert
  • Horsman, Joseph
  • Kritzer, Svetlana
  • Kingsley, Grant
  • Jacobs, Aaron

Abstract

Described are methods of detecting modified nucleotide bases in a nucleic acid sample using specific DNA glycosylases to excise a modified nucleobase of interest. Prior to glycosylase treatment, DNA target fragment templates are copied by a DNA polymerase to produce a first complementary copy strand that preserves the genetic information of the DNA target fragment. Following glycosylase treatment, the DNA target fragment templates are copied by an abasic bypass polymerase to produce a second complementary copy strand that preserves the epigenetic information of the DNA target fragment. Comparison of the DNA sequences of the two complementary copy strands enables identification of the positions of the modified nucleobases in the DNA target fragment.

IPC Classes  ?

  • C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

83.

AKDIFDY

      
Application Number 233648200
Status Pending
Filing Date 2024-04-22
Owner F. Hoffmann-La Roche AG (Switzerland)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

(1) Préparations pharmaceutiques destinées à être utilisées en neurosciences.

84.

ALFSYNPRA

      
Application Number 233648400
Status Pending
Filing Date 2024-04-22
Owner F. Hoffmann-La Roche AG (Switzerland)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

(1) Préparations pharmaceutiques destinées à être utilisées en neurosciences.

85.

ALPHSYNTAG

      
Application Number 233648300
Status Pending
Filing Date 2024-04-22
Owner F. Hoffmann-La Roche AG (Switzerland)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

(1) Préparations pharmaceutiques destinées à être utilisées en neurosciences.

86.

AKDIFDY

      
Application Number 019016249
Status Pending
Filing Date 2024-04-19
Owner F. Hoffmann-La Roche AG (Switzerland)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations.

87.

COMBINATION THERAPY OF A GPRC5D TCB AND CD38 ANTIBODIES

      
Application Number EP2023077814
Publication Number 2024/079010
Status In Force
Filing Date 2023-10-09
Publication Date 2024-04-18
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Eckmann, Jan
  • Fauti, Tanja
  • Hage, Carina
  • Jacob, Wolfgang
  • Schneider, Meike
  • Umaña, Pablo
  • Weisser, Martin

Abstract

The present invention relates to the combination therapy of anti-GPRC5D/anti-CD3 bispecific antibodies with with CD38 antibodies.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61P 35/00 - Antineoplastic agents
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

88.

ANTIVIRAL COMPOUNDS

      
Application Number EP2023077946
Publication Number 2024/079067
Status In Force
Filing Date 2023-10-10
Publication Date 2024-04-18
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Edmonds, David James
  • Liang, Chungen
  • Yun, Hongying
  • Zhang, Bo
  • Zheng, Xiufang

Abstract

The invention provides viral protease inhibitors having the general formula (I) wherein the variables are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

IPC Classes  ?

  • C07K 5/062 - Dipeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
  • A61K 38/00 - Medicinal preparations containing peptides
  • A61P 31/14 - Antivirals for RNA viruses

89.

METHODS AND DEVICES FOR SIMULATION OF AGITATION STRESS ON LIQUIDS

      
Application Number EP2023078272
Publication Number 2024/079231
Status In Force
Filing Date 2023-10-12
Publication Date 2024-04-18
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Boiger, Gernot Kurt
  • Rosenthal, Florian

Abstract

The present invention relates to a method for simulation of quality impact of transportation on a liquid, and a two-dimensional shaker adapted to perform said method.

IPC Classes  ?

90.

FILLING APPARATUS AND METHOD FOR FILLING A REUSABLE RESERVOIR OF A MEDICAL DISPENSING DEVICE

      
Application Number EP2023078314
Publication Number 2024/079250
Status In Force
Filing Date 2023-10-12
Publication Date 2024-04-18
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIABETES CARE GMBH (Germany)
  • ROCHE DIABETES CARE, INC. (USA)
Inventor
  • Bauer, Andreas
  • Norrick, Nicklas
  • Markl, Kristina

Abstract

The present invention relates to a filling apparatus for filling a reusable reservoir of a medical dispensing device, the filling apparatus comprises a receiving portion for a reusable reservoir, a supply container for containing a liquid medication, a first connection port for fluidly connecting an inner volume of the reusable reservoir with the supply container, and a sterilization device that is configured for sterilizing the inner volume of the reusable reservoir. In order to provide an improved sterilization, the filling apparatus further comprises a discharging device for discharging deposit from the inner volume of the inner volume, wherein the sterilization device comprises a radiation source for providing a radiation for sterilizing the reusable reservoir. The reusable reservoir is housed in a radiation chamber.

IPC Classes  ?

  • A61M 5/142 - Pressure infusion, e.g. using pumps

91.

COMPUTER-IMPLEMENTED METHOD FOR DETECTING AT LEAST ONE ANALYTE IN A SAMPLE WITH A LASER DESORPTION MASS SPECTROMETER

      
Application Number EP2023078341
Publication Number 2024/079261
Status In Force
Filing Date 2023-10-12
Publication Date 2024-04-18
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Rempt, Martin
  • Seitz, Manuel Josef
  • Zuth, Christoph

Abstract

A computer-implemented method for detecting at least one analyte in a sample with a laser desorption mass spectrometer (220) is disclosed. The method comprises: a) at least one imaging step comprising imaging at least one reflective target (128) by using at least one imaging device (235), wherein the sample comprising the at least one analyte is applied to the reflective target (128); b) at least one sample recognition step comprising localizing at least one sample re- gion on the reflective target (128); and c) at least one analyte detection step comprising detecting the at least one analyte in the sample using surface assisted laser desorption ionization mass spectrometry (SALDI-MS) with the laser desorption mass spectrometer (220), wherein laser ir- radiation is applied to the reflective target (128) by using at least one laser source (222) of the laser desorption mass spectrometer (220) such that at least one ion of the at least one analyte is generated which is detected by using at least one of a mass analyzing unit (224) or an ion-mobility spectrometry device of the laser de- sorption mass spectrometer (220), wherein the laser irradiation is steered on the localized sample region by using at least one control device (237).

IPC Classes  ?

  • H01J 49/00 - Particle spectrometers or separator tubes
  • H01J 49/16 - Ion sources; Ion guns using surface ionisation, e.g. field-, thermionic- or photo-emission
  • H01J 49/04 - Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locks; Arrangements for external adjustment of electron- or ion-optical components

92.

ALFSYNPRA

      
Application Number 019015383
Status Pending
Filing Date 2024-04-18
Owner F. Hoffmann-La Roche AG (Switzerland)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations.

93.

ALPHSYNTAG

      
Application Number 019015870
Status Pending
Filing Date 2024-04-18
Owner F. Hoffmann-La Roche AG (Switzerland)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations.

94.

MEDICAL IMAGE ANALYSIS

      
Application Number EP2023070989
Publication Number 2024/078769
Status In Force
Filing Date 2023-07-28
Publication Date 2024-04-18
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Tran, Manuel
  • Lahiani, Amal
  • Dicente, Yashin
  • Klaiman, Eldad

Abstract

Computer-implemented methods for analysing a medical image are provided, the method comprising: obtaining a medical image; inputting the image into a machine learning model, the machine learning model trained with training medical images, by: obtaining a plurality of smaller image segments from the training medical images; obtaining an image embedding for each image segment; and processing the embeddings using one or more attention mechanisms comprising a B-cos transform. Related methods, products and systems are described.

IPC Classes  ?

  • G06N 3/045 - Combinations of networks
  • G06N 3/048 - Activation functions
  • G06N 3/09 - Supervised learning
  • G06N 3/096 - Transfer learning
  • G06T 7/00 - Image analysis
  • G06T 7/10 - Segmentation; Edge detection
  • G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks

95.

COMBINATION THERAPY OF A GPRC5D TCB AND PROTEASOME INHIBITORS

      
Application Number EP2023077813
Publication Number 2024/079009
Status In Force
Filing Date 2023-10-09
Publication Date 2024-04-18
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Eckmann, Jan
  • Fauti, Tanja
  • Hage, Carina
  • Jacob, Wolfgang
  • Schneider, Meike
  • Umaña, Pablo
  • Weisser, Martin

Abstract

The present invention relates to the combination therapy of anti-GPRC5D/anti-CD3 bispecific antibodies with proteasome inhibitors. The combination therapy may further comprise a glucocorticosteroid.

IPC Classes  ?

  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
  • A61P 35/00 - Antineoplastic agents
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

96.

COMBINATION THERAPY OF A GPRC5D TCB AND IMIDS

      
Application Number EP2023077823
Publication Number 2024/079015
Status In Force
Filing Date 2023-10-09
Publication Date 2024-04-18
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Eckmann, Jan
  • Fauti, Tanja
  • Hage, Carina
  • Jacob, Wolfgang
  • Schneider, Meike
  • Umaña, Pablo
  • Weisser, Martin

Abstract

The present invention relates to the combination therapy of anti-GPRC5D/anti-CD3 bispecific antibodies with IMiDs. The combination therapy may further comprise a glucocorticosteroid.

IPC Classes  ?

  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61P 35/00 - Antineoplastic agents
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

97.

METHOD FOR SENSOR CALIBRATION

      
Application Number EP2023077850
Publication Number 2024/079022
Status In Force
Filing Date 2023-10-09
Publication Date 2024-04-18
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventor
  • Koenig, Iwo
  • Kostadinovic, Milenko
  • Perala, Scott

Abstract

An in-vitro diagnostic (IVD) analyzer (200) comprising at least one sensor (212) located in a flow-through sensor path (211) of detecting unit and requiring at least one oxygenated calibration fluid (221', 222') for calibration is herein disclosed. The IVD analyzer (200) further comprises a fluid-supply unit (220) comprising at least one deoxygenated calibration fluid (221, 222), a fluid-selection valve (230) and at least one oxygenation tubing (215, 216) having two ends connected to the fluid-selection valve (230) as a loop, wherein the oxygenation tubing (215, 216) comprises oxygen-permeable walls, and wherein the IVD analyzer (200) further comprises a pump (240) and a controller (250) configured to control the pump (240) and the fluid-selection valve (230) for transporting deoxygenated calibration fluid (221, 222) into the oxygenation tubing (215, 216), to wait a predetermined time required for oxygenation of the deoxygenated calibration fluid (221, 222) via oxygen uptake from ambient air through the tubing walls, and to transport the thereby obtained oxygenated calibration fluid (221', 222') into the sensor path (211) for calibration of the at least one sensor (212). A respective automatic method of calibrating at least one sensor (212) is herein also disclosed.

IPC Classes  ?

  • C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • G01N 33/96 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
  • G01N 27/327 - Biochemical electrodes

98.

METHOD FOR CLASSIFYING CELLS

      
Application Number EP2023077950
Publication Number 2024/079069
Status In Force
Filing Date 2023-10-10
Publication Date 2024-04-18
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Essig, Katharina
  • Glasmacher, Elke
  • Marr, Carsten
  • Schmich, Fabian
  • Shetab Boushehri, Sayedali

Abstract

Herein is reported a method for classifying cells in a cell mixture, wherein the mixture comprises T-cells and B-cells, comprising the steps of first applying at least labelled antibodies binding to F-actin, MHCII and CD3 to the cell mixture to obtained a labelled cell mixture, wherein the antibodies are each labelled with a dye, wherein the dyes have different (non-overlapping) emission wavelengths, second acquiring at least one image of the cell mixture, and third classifying the cells in the cell mixture to be an isolated cell if the cell is a single cell, is F-Actin positive and is MHCII positive and CD3 negative, or is MHCII negative and CD3 positive, or to be a doublet or multiplet of cells if the cell is an aggregate of two or three cells, is F- Actin positive, MHCII positive and CD3 positive.

IPC Classes  ?

  • G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

99.

DISEASE CHARACTERISATION

      
Application Number EP2023078390
Publication Number 2024/079279
Status In Force
Filing Date 2023-10-12
Publication Date 2024-04-18
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
  • ROCHE MOLECULAR SYSTEMS, INC. (USA)
Inventor
  • Klaiman, Eldad
  • Duroux, Diane
  • Etz Hadar, Ofir
  • Gildenblat, Jacob
  • King, Michael
  • Van Steen, Kristel
  • Vladimirova, Antoaneta
  • Wohlfart, Christian

Abstract

Computer-implemented methods of providing a disease diagnosis or prognosis for a patient are described. These comprise generating individual networks, each individual network comprising a plurality of nodes and edges between pairs of the nodes, wherein each node is indicative of a biological factor in biological data for an individual, and each edge is indicative of a relationship between a pair of biological factors corresponding to the nodes that the edge connects for the respective individual; determining the value of one or more similarity metrics between one or more individual networks generated for the patient and one or more individual networks generated for other individuals in the plurality of individuals; and predicting a diagnosis or prognosis for the patient using a machine learning model that takes as input the values of one or more similarity metrics.

IPC Classes  ?

  • G16B 40/20 - Supervised data analysis
  • G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

100.

SWALLOWING MEASUREMENT

      
Application Number EP2023077723
Publication Number 2024/074686
Status In Force
Filing Date 2023-10-06
Publication Date 2024-04-11
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • HOFFMANN-LA ROCHE INC. (USA)
Inventor
  • Kuster, Roman Peter
  • Perumal, Thanneer Malai

Abstract

A diagnostic device configured to count a number of swallows of a user, the device comprising: at least one processor; a user interface; one or more sensors associated with the device; and a memory storing computer-readable instructions that, when executed by the at least one processor, cause the diagnostic device to: prompt, via the user interface, the user to provide a user input via the one or more sensors associated with the device each time the user is at a predetermined point during a swallowing action; receive a plurality of inputs via the one or more sensors, each user input corresponding to a respective time at which the user is at a predetermined point during the swallowing action; generate, in response to receiving each user input, a timestamp associated with the respective user input; apply a counting model to data comprising the plurality of generated timestamps, wherein the counting model is configured to calculate a number of swallows of a user by counting the total number of timestamps in the data comprising the plurality of generated timestamps; and outputting the calculated number of swallows.

IPC Classes  ?

  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  1     2     3     ...     80        Next Page